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Background: At present only few studies directly compare the diagnostic yield of endobronchial ultrasound
guided fine needle aspiration (EBUS-FNA) and transcervical video-assisted mediastinoscopy (TM) for mediastinal
lymph node staging in patients with NSCLC. If and when EBUS-FNA may replace TM as Gold Standard remains
controversial.
Methods: From April 2008 to December 2009, 36 patients with mediastinal lymphadenopathy underwent
simultaneous EBUS-FNA/ TM at our institution. Among them were 26 patients with confirmed or suspected NSCLC.
Results: A total of 133 samples were obtained by EBUS-FNA and 157 samples by TM. EBUS-FNA achieved
significantly less conclusive, but more indeterminate pathological results in comparison to TM (78.7% vs. 98.6%,
p< 0.001; 14.9% vs. 1.4%, p= 0.007). Less paratracheal nodes were sampled by EBUS-FNA (right: 46.2% vs. 88.5%,
p= 0.003; left: 23.1% vs. 65.4%, p= 0.005), while sampling rates in the subcarinal localisation were comparable (96.2%
vs. 80.8%, p=NS). Among patients with confirmed NSCLC and conclusive EBUS-FNA/ TM findings (n = 18), the
prevalence of N2/N3 disease was 66.7% (n = 12) according to TM findings. Diverging nodal stages were found in
five patients (27.8%). Three patients who were N2 negative in EBUS-FNA were upstaged to N2 or N3 by TM, two
patients with N2 status in EBUS-FNA were upstaged to N3 by TM.
Conclusions: Compared to TM, EBUS-FNA had a lower diagnostic yield and resulted in systematic mediastinal
nodal understaging. At this point we suggest corroborating negative EBUS-FNA results by transcervical
mediastinoscopy.
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Accurate mediastinal nodal assessment is crucial to
stratify patients with NSCLC for adequate therapy, in-
cluding (neo)adjuvant and definitive treatment protocols
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reproduction in any medium, provided the ormediastinal nodal staging, endobronchial ultrasound
guided fine needle aspiration (EBUS-FNA) has gained
widespread acceptance as alternative diagnostic modality
in recent years [1-4]. Literature reviews and meta-
analyses of EBUS-FNA in lung cancer staging show a
sensitivity of 88% to 93%, as well as a specificity of 100%
[5,6]. Current American College of Chest Physicians
(ACCP) guidelines for invasive mediastinal staging of
lung cancer acknowledge that EBUS-FNA has a similar
sensitivity although a higher false negative rate when
compared to video-assisted mediastinoscopy (90% vs.
90% and 24% vs. 10%, respectively) [7].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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FNA may replace TM as gold standard in mediastinal
nodal assessment prior to curative lung resection. Very
few published studies directly compare the diagnostic
value of EBUS-FNA and TM in this regard. While cer-
tain groups report lower sensitivity and similar specifi-
city of EBUS-FNA [8], other postulate higher sensitivity
and negative predictive value of EBUS-FNA [9].
We launched a prospective trial set to compare the
diagnostic value of EBUS-FNA and TM for mediastinal
nodal staging in patients with confirmed or suspected
NSCLC by performing both procedures concomitantly.
Methods
From April 2008 to December 2009, 117 patients were
screened for enrolement in the present study. Our inclu-
sion criteria consisted of histologically proven or sus-
pected NSCLC, eligibility for lung resection and adult
age (> 18 years). The exclusion criteria included distant
metastasis, neoadjuvant therapy, N2-bulky disease, pre-
vious mediastnoscopy, pregnancy, coagulation or platelet
function disorder, ongoing anticoagulation therapy. A
total of 26 consecutive patients were subsequentially
enlisted and underwent concomitant EBUS-FNA/ TM
for mediastinal nodal assessement in accordance with
current ESTS guidelines after multidisciplinary tumour
board approval. Sixty-nine patients were excluded due to
refusal of simultaneous EBUS-FNA and TM. Enrolement
modalities and final diagnoses are presented as chartflow
(Figure 1). Standard diagnostic workup prior to simultan-
eous EBUS-FNA/TM included medical history, phyiscal
examination, laboratory testing, bronchoscopy, cMRIFigure 1 Chartflow demonstrating patient enrollment and final diagnand PET/CT. This study conforms to the principles out-
lined in the Declaration of Helsinki and approval of our
IRB was obtained. Every patient was informed about all
procedures and gave his/her written informed consent.
All patients underwent simultaneous EBUS-FNA and
TM by a single thoracic surgeon experienced in both
procedures. After induction of general anaesthesia and
orotracheal intubation, EBUS-FNA was performed using
a flexible ultrasound bronchoscope (Olympus BF−
UC180F, Olympus Medical Systems Europe, Hamburg,
Germany) connected to an ultrasound processor (Olym-
pus EU−C60). Cytological specimens were obtained by
means of 22-guage needles for transbronchial aspiration
(Olympus NA−201 SX-4022, Olympus Medical Systems
Europe, Hamburg, Germany). The technique was similar
to that previously described by Yasufuku et al. [10]. Me-
diastinal and hilar lymph nodes (LN) were systematically
examined and sampled with at least 3 passes at each
visualized LN under direct ultrasound guidance. To pre-
vent contamination, different needles were used for each
LN station. LN was sampled in order of N3, N2 and
then N1. Afterwards, transcervical mediastinoscopy was
performed using a standard video-mediastinoscope
(Storz, Germany) according to the standard technique
first described by Carlens. Both our cytologist and path-
ologist were blinded, and rapid cytological evaluation or
intraoperative frozen section analysis were available only
in case of highly suspect N3 nodes. Otherwise no infor-
mation on cytological and histological findings was
passed on intraoperatively.
Descriptive statistics are presented as mean ± standard
deviation. Categorical variables are expressed asosis.
Table 2 Analysis of all sampled lymph node stations
EBUS-FNA Mediastinoscopy p value
Sampled LN stations 47 71
Total sample number 133 157
Sampled LN stations
per patient
1.7 ± 0.9 2.7 ± 1.0 0.001
Samples per LN station 2.8 ± 1.6 2.2 ± 1.3 <0.001
Conclusive finding 37 (78.7%) 70 (98.6%) <0.001
Indeterminate finding 7 (14.9%) 1 (1.4%) 0.007
Non-representative
material
3 (6.4%) 0 (0%) 0.061
Table 3 Analysis of mediastinal lymph nodes




Sample of N2 nodes
per patient
2.7 ± 1.6 2.2 ± 1.3 0.040
Sampling rate
Right paratracheal 46.2% (n = 12) 88.5% (n = 23) 0.003
Left paratracheal 23.1% (n = 6) 65.4% (n = 17) 0.005
Subcarinal 96.2% (n = 25) 80.8% (n = 21) 0.191
Samples per station
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tinuous data were compared using the student t-test.
Statistical significance was assumed if p< 0.05. All statis-
tical evaluation was performed using SPSS (version 16.0
for Windows; SPSS, Inc., Chicago, IL).
Results
A total of 26 patients (64.5 ± 11.3 years, 12 males) were
enrolled in this study. All showed cT1 and cT2 tumour
lesions except for one patient with a cT3 tumour.
Results of preoperative clinical mediastinal nodal staging
are listed in Table 1.
Analyses of all sampled LN stations are presented in
Table 2. A total of 133 samples from 47 LN stations
were obtained by EBUS-FNA as well as 157 samples
from 71 LN stations by TM. The size of LN sampled by
EBUS-FNA was 11.1 ± 6.1 mm. Compared to TM, there
were fewer LN stations sampled by EBUS-FNA, but
more samples per LN station were obtained. In terms of
pathological findings, EBUS-FNA achieved significantly
less conclusive, but more indeterminate results in com-
parison to TM. Non-representative samples were only
found in EBUS-FNA (n = 3).
A detailed analysis of sampled mediastinal LN is pre-
sented in Table 3. EBUS-FNA achieved biopsy of para-
tracheal LN in fewer patients compared to TM. Fewer
samples were also obtained by EBUS-FNA at these LN
stations. The subcarinal station was sampled in more
patients by EBUS-FNA, however without statistical sig-
nificance. More samples were obtained by EBUS-FNA at
the subcarinal level. Among patients with confirmed
NSCLC who had both conclusive EBUS-FNA and TM
findings (n = 18), prevalence of N2/N3 disease was 66.7%
(n = 12) according to TM findings. Diverging nodal
stages were found in five patients (27.8%). Three patients
who were N2 negative in EBUS-FNA were upstaged to
N2 or N3 by TM, two patients with N2 status in EBUS-
FNA were upstaged to N3 by TM (Table 4). Understa-
ging resulted from false negative findings in EBUS-FNA
in three patients. In two patients paratracheal LN sta-
tions were not sampled by EBUS-FNA, also leading to
nodal understaging.
Neither EBUS-FNA nor TM lead to postoperative com-
plications. Over our observation period, nine patients
underwent curative lung resection with systematic radicalTable 1 Results of preoperative clinical mediastinal nodal





cN3 3 (11.5%)lymphadenectomy. The postsurgical LN staging was in ac-
cordance to TM results in all patients. Three patients
received adjuvant chemotherapy due to single station N2
disease determinated by both TM and postsurgical patho-
logical examination. A high prevalence of N2/N3 disease
allowed for postsurgical LN staging only in nine out of 26
patients. This prevented us from extrapolating sensitivity,
specificity, diagnostic accuracy and false-negative rate for
each procedure.
Discussion
In the present study, EBUS-FNA and TM were directly
compared for mediastinal nodal assessment in patients
with proven or suspected NSCLC. In this series, EBUS-
FNA had a lower diagnostic yield and resulted in sys-
tematic understaging of mediastinal LN metastases,
mainly due to false negative findings. These results are
generally in line with recent meta-analyses evaluatingRight paratracheal 1.3 ± 0.3 2.1 ± 0.4 0.002
Left paratracheal 1.4 ± 0.3 1.6 ± 0.3 0.058
Subcarinal 1.8 ± 0.4 1.2 ± 0.2 0.007
Pathological N-staging*
Negative N2/3 9 6
N2 7 7
N3 2 5
* n = 18 patients with confirmed NSCLC and both conclusive EBUS-FNA and
TM findings.
Table 4 Discordant mediastinal nodal staging between
EBUS-FNA and TM
EBUS-FNA Mediastinoscopy
Pts Stage Results of single
LN stations*
Stage Results of single
LN stations*
#2 N2 neg. neg. (2), neg. (4), neg. (3) N3 neg. (2), pos. (1), pos. (2)
#11 N2 neg. neg. (2), neg. (2), neg. (2) N2 pos. (7), NS, NS
#15 N2 pos. (2), pos. (3), neg. (1) N3 NS, pos. (4), pos. (3)
#19 N2 NS, pos. (2), NS N3 pos. (6), pos. (2), pos. (1)
#20 N2 neg. NS, neg. (7), NS N2 pos. (2), neg. (2), NS
* The results of single LN stations are presented in order of right paratracheal,
subcarinal and left paratracheal station. The sample number of single LN
station is presented in the parasenthesis. NS = not sampled.
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diastinal LN staging in lung cancer patients. Among
them is a meta-analysis on which the current ACCP
guidelines are based, where EBUS-FNA had a false nega-
tive rate as high as 24% [7]. A further meta-analysis of
Gu and co-workers acknowledged that EBUS-FNA
achieves an overall sensitivity of 76% in all patients, in-
cluding those with negative pre-operative CT and/or
PET/CT scans [6]. In a current study of Defranchi and
coworkers, 29 patients with suspected or confirmed lung
cancer had negative EBUS-FNA findings and underwent
subsequent mediastinoscopy. TM discerned metastatic
nodes in eight of these patients (28%) [11].
In recent years EBUS-FNA has gained widespread ac-
ceptance as an alternative diagnostic modality for medias-
tinal staging in NSCLC. Despite technical improvements
(real-time ultrasound guidance) and adequate techniques,
the inherent limit of small tissue volumes obtainable
through FNA-procedures persists. Small metastatic
tumour deposits are more likely to be missed by needle
aspiration than by extensive biopsy. As pointed out by
Dr. Shrager in his comment, a needle-based technique can
hardly achieve the same reliability than a surgical proced-
ure that allows for extensive tissue sampling [12]. These
findings are corroborated by various studies of conven-
tional transbronchial needle aspiration in mediastinal LN
staging demonstrating that 19-gauge needles, which pro-
vide a core of tissue and allow for histological evaluation,
are more sensitive than thinner cytology needles (21- or
22-gauge) [13,14].
Recent reports on comparable or even higher sensitiv-
ity of EBUS-FNA are mostly based on analyses of
enlarged mediastinal LN in cohorts with high prevalence
of malignancy. In a study of Ernst et al. comparing
EBUS/FNA and TM in n= 66 patients, only radiologically
enlarged mediastinal LN (mean short axis 15 mm) were
sampled and analyzed [9]. Certain factors may have
biased their study in favour of EBUS-FNA: While TM
was performed by eight different surgeons EBUS-FNA
was performed by just three endoscopists. Secondly, anunusually high rate of non-diagnostic procedures (25.8%,
17 out of 66 patients) was encountered in their study.
Additionally, they found a significantly higher accuracy
of EBUS-FNA in subcarinal LN stations compared to
TM, while diagnostic rates from paratracheal LN did not
differ between both procedures and explained this obser-
vation by postulating that posterior subcarinal LN are be-
yond reach of mediastinoscopy. This diverges from our
findings, as we had comparable sampling rates in subcar-
inal LN for EBUS-FNA and TM. Finally, some EBUS-
FNA cases were performed within one week prior to TM,
potentially rendering subsequent LN sampling more
difficult.
Mediastinal nodal staging in NSCLC is initially based on
the results of conventional imaging. To confirm nodal in-
volvement in radiologically enlarged mediastinal LN, ei-
ther EBUS-FNA or TM are reasonable [4,7]. Even in this
patient subset, negative results from EBUS-FNA should
be corroborated by TM. At present EBUS-FNA does not
appear to be reliable enough to categorically rule out
metastatic involvement of normal-sized mediastinal LN.
Additionally, paratracheal LN, particularly on the left side,
are technically difficult to visualize by EBUS-FNA and
small LN size and adherence to vessel wall render sam-
pling generally challenging [15]. In 2007, Yasufuku et al.
reported preliminary results of a prospective controlled
trial comparing EBUS-FNA and mediastinoscopy for me-
diastinal nodal staging of lung cancer. EBUS-FNA fol-
lowed by TM was performed in 33 patients with
confirmed or suspected NSCLC to determine suitability
for surgical resection. The mean short axis of the biopsied
LN was 6.7 mm. EBUS-FNA achieved lower sensitivity,
but comparable specificity and diagnostic accuracy when
compared to TM (76.9% vs. 84.6%, 100% vs. 100% and
90.9% vs. 93.9%, respectively). A discordant mediastinal
LN staging was found in five patients (15.3%) [8]. During
the 2011 AATS Meeting, the same group presented
updated results from their ongoing study based on 153
patients. They found no significant differences between
EBUS-FNA and TM in the diagnostic yield for mediastinal
nodal staging in NSCLC. The sensitivity, specificity, nega-
tive predictive value and diagnostic accuracy for medias-
tinal lymph node staging for EBUS-TBNA and MS were
84.3%, 100%, 92.7%, 94.8% and 86.3%, 100%, 93.6%, 95.4%,
respectively [16]. This very interesting development sug-
gests that EBUS-FNA may achieve the same diagnostic
value as TM in mediastinal nodal staging in very experi-
enced hands. It should be kept present that those results
were reported by leading experts in the field.
The authors do recognize various limitations of the
present study. They primarily include an inherent sin-
gle investigator bias and a modest sample size. On the
other hand, an interpersonal bias, which was common
to various previous comparative studies, was avoided.
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Our current results suggest that EBUS-FNA still has a
lower diagnostic yield than TM and may lead to system-
atic nodal understaging in patients with suspected or con-
firmed NSCLC. At present EBUS-FNA appears as not
reliable enough to safely rule out mediastinal nodal me-
tastases and we therefore encourage to still corroborate a
negative EBUS-FNA by transcervical mediastinoscopy.
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